1 Coverage Fell From 72% to 60%. Is Eli Lilly’s Weight

OmniAb (OABI) and Eli Lilly (LLY) announced a global collaboration to develop ion channel therapeutics. Lilly will pay $370M in milestones plus royalties. OABI reported Q2 2026 revenue of $13.4M, up from $3.9M, while LLY reported $23B revenue, up 48% YoY. OABI's model focuses on licensing, while LLY's growth is driven by GLP-1 treatments.

Employer coverage of GLP-1 weight-loss drugs, including Eli Lilly's Zepbound and Mounjaro, dropped from 72% to 60% between 2025 and 2026. Despite this, Lilly's Q2 revenue grew 47.67% YoY to $22.97 billion, with Zepbound and Mounjaro contributing $4.93 billion and $9.94 billion, respectively. The decline in coverage is due to employers' budget constraints and the long-term nature of health benefits. Lilly is mitigating the impact through direct-to-consumer channels and lower-cost programs.

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

Eli Lilly's Mounjaro (tirzepatide) received FDA approval to reduce cardiovascular risk in type 2 diabetes patients. The approval follows positive results from the SURPASS-CVOT trial, showing an 8% lower rate of major adverse cardiovascular events compared to Trulicity. Mounjaro is the first GIP and GLP-1 receptor agonist with this indication, according to the company.

Eli Lilly's Mounjaro (tirzepatide) received FDA approval to reduce cardiovascular risk in adults with type 2 diabetes. The approval follows a trial showing an 8% lower rate of cardiovascular events compared to Trulicity (dulaglutide). Mounjaro is already approved for blood sugar control and is the top-prescribed branded diabetes medicine in the U.S.

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.